PRP (Autologous Platelet rich plasma) may improve hip arthroscopy patients outcome.

In patients undergoing hip arthroscopy, how would platelet rich plasma, compared with placebo, improve post operative outcome in the short and long term.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000984998

Enrollment

105

Registered

2011-09-15

Start date

2011-09-20

Completion date

2012-06-29

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hip arthroscopy is a surgical treatment technique which commonly address intra articular cartilage and labral pathologies. There is a growing evidence that PRP can improve articular cartilage healing, both when applied during surgery or as a sole method of treatment, when prescribed for the proper indication. PRP injection has been proposed as a novel treatment modality for the management of articular cartilage injuries of the knee, hip and ankle. Even though high level of clinical evidence is lacking, basic research supports the use of PRP derived growth factors to improve tissue healing. There are few published clinical studies on the use of PRP in cartilage pathology. The study hypothesis is that the new treatment (PRP) would improve patients outcome after arthroscopic treatment for FAI (hip impingement).

Interventions

The treatment group would be treated with platelets concentrate prepared from their own blood (which was drown by 4 regular 5 cc blood collecting tubes). The concentrate will be applied to the operated area (hip) 24 hours after the surgery via a drainage left at the site during the procedure.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

16 Years to 50 Years

Healthy volunteers

Inclusion criteria

1. healthy patients undergoing hip Arthroscopy due to FAI 2. Ages 16-50 3. No OA changes according to XR and surgery observation 4. No previous hip surgery 5. No other influential disabilities in lower limbs 6. No chronic use of NSAID, steroids or chemotherapy drugs

Exclusion criteria

Non-ambulating patients, those with severe advanced osteoarthritic changes on radiological imaging, patients with suspected previous joint infection, pregnant or lactating women, open wounds or skin ulcers and those taking anticoagulants or having a prolonged bleeding time were excluded.

Outcome results